Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Study of TAR-200 in Combination With Nivolumab (OPDIVO) in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy

NCT03518320 is registered in ClinicalTrials.gov with Taris Biomedical LLC as lead sponsor.

NCT NCT03518320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03518320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Study of TAR-200 in Combination With Nivolumab (OPDIVO) in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy
Lead sponsor
Taris Biomedical LLC
Phase
Phase 1
Overall status
Terminated
Start date
January 2, 2019
Completion date
December 11, 2019
Enrollment
13 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer tnm staging distant metastasis (m) m0, bladder cancer tnm staging primary tumor (t) t2, bladder cancer tnm staging primary tumor (t) t2a, bladder cancer tnm staging primary tumor (t) t2b, bladder cancer tnm staging primary tumor (t) t3, bladder cancer tnm staging primary tumor (t) t3a, bladder cancer tnm staging primary tumor (t) t3b, bladder cancer tnm staging regional lymph node (n) n0, bladder cancer tnm staging regional lymph node (n) n1